Condition Lookup

Alpha-1 Antitrypsin Deficiency

Sub-category: Metabolic and Genetic Liver Disorders

Symptoms:
fatigue; jaundice; unexplained liver dysfunction; dyspnea; recurrent respiratory infections; unintentional weight loss

Root Cause:
Mutation in the SERPINA1 gene leading to misfolded alpha-1 antitrypsin protein that accumulates in the liver and reduces its protective effect in the lungs.

How it's Diagnosed: videos
Blood tests to measure alpha-1 antitrypsin levels, genetic testing, liver biopsy, and pulmonary function tests.

Treatment:
Management of liver and lung symptoms; augmentation therapy for lung protection, and in severe cases, liver or lung transplantation.

Medications:
Alpha-1 proteinase inhibitors (e.g., Prolastin , Zemaira , Glassia ) for lung protection. There are no direct medications for the liver dysfunction, though supportive therapies are used.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 2,500 to 1 in 5,000 individuals of European descent.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, smoking (worsens lung symptoms), exposure to lung irritants.

Prognosis: The expected outcome or course of the condition over time.
Variable; lung and liver disease can progress if untreated. Augmentation therapy and avoiding lung irritants can improve outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Liver cirrhosis, hepatocellular carcinoma, chronic obstructive pulmonary disease (COPD), emphysema, and respiratory failure.

Viral Hepatitis (A, B, C, D, E)

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Hepatitis

Symptoms:
jaundice; fatigue; abdominal pain; nausea; vomiting; loss of appetite; dark urine; pale stools

Root Cause:
Infection of the liver caused by hepatitis viruses (A, B, C, D, or E), leading to liver inflammation and, in some cases, chronic liver disease.

How it's Diagnosed: videos
Blood tests to identify viral markers (e.g., HBsAg, anti-HCV, anti-HAV), liver function tests, imaging studies like ultrasound, and sometimes liver biopsy.

Treatment:
Treatment depends on the type of hepatitis. Includes antiviral medications, supportive care (hydration, rest), and, in severe cases, liver transplantation.

Medications:
Hepatitis B - Tenofovir (antiviral, nucleotide analog), Entecavir (antiviral, nucleoside analog). Hepatitis C - Sofosbuvir and Velpatasvir (direct-acting antiviral agents). Hepatitis A & E - No specific antiviral treatment; supportive care. Hepatitis D - Pegylated interferon-alpha (antiviral, immune modulator).

Prevalence: How common the health condition is within a specific population.
Affects millions globally; Hepatitis B and C are the most common chronic forms, with over 250 million and 70 million people affected worldwide, respectively.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Unprotected sex, intravenous drug use, sharing needles, blood transfusions, close contact with infected individuals, and poor sanitation.

Prognosis: The expected outcome or course of the condition over time.
Acute hepatitis often resolves with supportive care, but chronic hepatitis (especially B and C) can lead to cirrhosis, liver failure, or hepatocellular carcinoma if untreated.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Chronic liver disease, cirrhosis, liver cancer, and liver failure.

Autoimmune Hepatitis

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Hepatitis

Symptoms:
fatigue; jaundice; abdominal discomfort; joint pain; skin rashes; spider angiomas; loss of appetite

Root Cause:
The immune system attacks healthy liver cells, leading to inflammation and progressive liver damage.

How it's Diagnosed: videos
Blood tests (autoantibodies like ANA, ASMA, LKM-1), liver function tests, imaging studies, and liver biopsy.

Treatment:
Immunosuppressive therapy and monitoring of liver function.

Medications:
Prednisone (corticosteroid to reduce inflammation). Azathioprine (immunosuppressant to maintain remission). Mycophenolate mofetil or tacrolimus (alternative immunosuppressants for refractory cases).

Prevalence: How common the health condition is within a specific population.
Rare, with an estimated prevalence of 10–20 per 100,000 people worldwide; more common in females.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Genetic predisposition, female gender, environmental triggers like infections or certain medications.

Prognosis: The expected outcome or course of the condition over time.
Good with early treatment; untreated cases can progress to cirrhosis or liver failure.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Cirrhosis, liver failure, and increased risk of hepatocellular carcinoma.

Non-Alcoholic Steatohepatitis (NASH)

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Non-Alcoholic Fatty Liver Disease (NAFLD)

Symptoms:
fatigue; mild abdominal discomfort; enlarged liver (hepatomegaly); jaundice (in advanced cases); asymptomatic in early stages

Root Cause:
Fat accumulation in the liver causing inflammation and damage, not related to alcohol use.

How it's Diagnosed: videos
Liver function tests, imaging (ultrasound, CT, or MRI), and liver biopsy.

Treatment:
Lifestyle changes (weight loss, healthy diet, exercise), management of comorbidities (diabetes, dyslipidemia).

Medications:
Vitamin E (antioxidant for non-diabetic patients). Pioglitazone (insulin sensitizer, for patients with type 2 diabetes). Obeticholic acid (under study for reducing liver inflammation and fibrosis).

Prevalence: How common the health condition is within a specific population.
Affects about 3–5% of the global population; more common in individuals with obesity or diabetes.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Obesity, type 2 diabetes, metabolic syndrome, dyslipidemia, sedentary lifestyle.

Prognosis: The expected outcome or course of the condition over time.
Variable; can remain stable with lifestyle modifications or progress to cirrhosis and liver failure if untreated.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Cirrhosis, liver failure, hepatocellular carcinoma, cardiovascular disease.

Alcoholic Cirrhosis

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Liver Cirrhosis

Symptoms:
fatigue; jaundice (yellowing of skin and eyes); abdominal swelling (ascites); loss of appetite; nausea; easy bruising or bleeding; spider angiomas (small, spider-like blood vessels visible under the skin); confusion or drowsiness (hepatic encephalopathy); dark urine; pale stools

Root Cause:
Chronic alcohol abuse damages liver cells, leading to scarring (fibrosis) and loss of liver function.

How it's Diagnosed: videos
Diagnosis involves medical history review (alcohol consumption), physical examination, blood tests (liver function tests, INR, bilirubin), imaging studies (ultrasound, CT, or MRI), and possibly a liver biopsy to confirm.

Treatment:
Treatment focuses on abstinence from alcohol, nutritional support, managing complications (e.g., ascites, hepatic encephalopathy), and, in severe cases, liver transplantation.

Medications:
Medications include diuretics (e.g., spironolactone or furosemide ) to manage fluid retention, lactulose or rifaximin to treat hepatic encephalopathy, and vitamin supplementation (thiamine , folate, vitamin D) to address deficiencies.

Prevalence: How common the health condition is within a specific population.
Alcoholic cirrhosis affects approximately 10–15% of heavy drinkers and accounts for around 50% of cirrhosis cases globally.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Chronic heavy alcohol consumption, genetic predisposition, malnutrition, co-existing liver diseases (e.g., hepatitis C).

Prognosis: The expected outcome or course of the condition over time.
Prognosis depends on alcohol abstinence and severity at diagnosis. Without abstinence, survival is often less than 5 years. Early abstinence improves outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Portal hypertension, variceal bleeding, hepatic encephalopathy, liver failure, spontaneous bacterial peritonitis, hepatocellular carcinoma (liver cancer).

Cryptogenic Cirrhosis

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Liver Cirrhosis

Symptoms:
fatigue; jaundice; abdominal swelling; unexplained weight loss; loss of appetite; easy bruising; spider angiomas; itching (pruritus); dark urine

Root Cause:
Cirrhosis without an identifiable cause, often associated with undiagnosed non-alcoholic fatty liver disease (NAFLD), insulin resistance, or autoimmune conditions.

How it's Diagnosed: videos
Exclusion of known causes of liver disease (e.g., alcohol, hepatitis viruses, autoimmune markers); imaging (ultrasound, CT, MRI); liver biopsy to assess fibrosis and exclude other pathologies.

Treatment:
Addressing underlying factors (e.g., managing metabolic syndrome, weight loss, controlling diabetes), supportive care, and managing complications like ascites and portal hypertension.

Medications:
Diuretics (spironolactone or furosemide ) for ascites, lactulose or rifaximin for hepatic encephalopathy, and vitamin supplementation. No specific medications target cryptogenic cirrhosis.

Prevalence: How common the health condition is within a specific population.
Accounts for 5–30% of cirrhosis cases worldwide, often diagnosed in advanced stages.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Metabolic syndrome, obesity, diabetes, genetic predisposition, undiagnosed or untreated fatty liver disease.

Prognosis: The expected outcome or course of the condition over time.
Variable; depends on stage at diagnosis and response to treatment. Early management of risk factors improves outcomes. Advanced cases may require liver transplantation.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Portal hypertension, variceal bleeding, hepatic encephalopathy, liver failure, hepatocellular carcinoma.

Cirrhosis from Hepatitis or Fatty Liver Disease

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Liver Cirrhosis

Symptoms:
fatigue; jaundice; abdominal swelling; loss of appetite; nausea; easy bruising or bleeding; confusion or drowsiness; dark urine; pale stools

Root Cause:
Chronic inflammation from hepatitis B, hepatitis C, or non-alcoholic fatty liver disease (NAFLD) leads to progressive fibrosis and cirrhosis.

How it's Diagnosed: videos
Blood tests for liver function, viral hepatitis markers, imaging (ultrasound, transient elastography), and sometimes a liver biopsy for fibrosis grading.

Treatment:
Antiviral medications for hepatitis (e.g., entecavir or tenofovir for HBV; direct-acting antivirals for HCV), weight loss and diabetes management for NAFLD, and supportive care for complications.

Medications:
Antivirals (e.g., sofosbuvir , velpatasvir ), diuretics for fluid retention, lactulose or rifaximin for hepatic encephalopathy, and nutritional supplements as needed.

Prevalence: How common the health condition is within a specific population.
Cirrhosis from hepatitis or fatty liver disease is a leading cause of liver-related morbidity worldwide, with NAFLD prevalence rising due to obesity epidemics.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Chronic hepatitis B or C infection, obesity, diabetes, metabolic syndrome, heavy alcohol consumption, genetic factors.

Prognosis: The expected outcome or course of the condition over time.
Depends on the underlying cause and stage at diagnosis. With treatment of the underlying condition (e.g., hepatitis antivirals or weight management), progression can be slowed. Advanced cases may require liver transplantation.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Portal hypertension, variceal bleeding, hepatic encephalopathy, liver failure, hepatocellular carcinoma.

Liver Metastases

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Liver Tumors

Symptoms:
jaundice; right upper quadrant pain; unintended weight loss; fatigue; loss of appetite; fever

Root Cause:
Secondary liver tumors arising from the spread of primary cancers, commonly from the colon, rectum, breast, pancreas, or lung.

How it's Diagnosed: videos
Imaging studies (CT, MRI, PET scans), liver function tests, biopsy to confirm metastatic origin.

Treatment:
Systemic chemotherapy targeting the primary cancer, localized treatments such as radiofrequency ablation or TACE, surgical resection when feasible.

Medications:
Chemotherapeutic agents like 5-fluorouracil (5-FU), oxaliplatin , and irinotecan ; targeted therapies such as bevacizumab or cetuximab , depending on the primary cancer. These are classified as cytotoxic agents and monoclonal antibodies.

Prevalence: How common the health condition is within a specific population.
Liver metastases are more common than primary liver cancers; about 50% of patients with colorectal cancer develop liver metastases.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Primary cancer in organs with venous drainage to the liver, late-stage cancers, lack of primary cancer treatment.

Prognosis: The expected outcome or course of the condition over time.
Depends on the primary cancer and extent of liver involvement; potentially curative with localized therapies in selected cases, but overall poor prognosis for widespread disease.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Liver failure, biliary obstruction, infection, severe cachexia.

Benign Liver Tumors (e.g., Hemangioma, Focal Nodular Hyperplasia)

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Liver Tumors

Symptoms:
asymptomatic; right upper quadrant discomfort; bloating; nausea; rarely, a palpable mass

Root Cause:
Non-cancerous growths in the liver; hemangiomas are vascular malformations, and focal nodular hyperplasia is a hyperplastic response to vascular abnormalities.

How it's Diagnosed: videos
Often incidental on imaging (ultrasound, CT, or MRI), confirmed with characteristic imaging patterns; rarely requires biopsy.

Treatment:
Usually no treatment necessary; symptomatic lesions may require surgical resection or embolization.

Medications:
None typically required; treatment focuses on monitoring or surgical intervention if needed.

Prevalence: How common the health condition is within a specific population.
Hemangiomas are the most common benign liver tumors, affecting up to 5% of the population. Focal nodular hyperplasia is less common, occurring in 0.3%-3% of adults.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Female gender, use of oral contraceptives (for hepatic adenomas), underlying vascular abnormalities.

Prognosis: The expected outcome or course of the condition over time.
Excellent; benign tumors do not progress to malignancy, and most remain asymptomatic.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Rare; large hemangiomas may rupture, causing bleeding, or compress nearby structures.

Hemochromatosis

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Metabolic and Genetic Liver Disorders

Symptoms:
fatigue; joint pain; abdominal pain; bronze or gray skin discoloration; weakness; diabetes; irregular heartbeat; liver dysfunction

Root Cause:
Excessive iron absorption and accumulation in tissues due to a genetic mutation, typically in the HFE gene.

How it's Diagnosed: videos
Blood tests (serum ferritin, transferrin saturation), genetic testing, liver biopsy, MRI for iron quantification.

Treatment:
Regular therapeutic phlebotomy to remove excess iron, iron chelation therapy in cases where phlebotomy is not possible.

Medications:
Iron chelators such as deferoxamine , deferiprone , and deferasirox ; these are used to bind excess iron and promote its excretion in severe cases or when phlebotomy is not feasible.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 200-500 individuals of Northern European descent; more common in men than women.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, genetic mutations (e.g., HFE C282Y and H63D mutations), being male (symptoms often manifest earlier in men).

Prognosis: The expected outcome or course of the condition over time.
Good with early diagnosis and management; untreated, it can lead to serious complications like liver cirrhosis, heart disease, and diabetes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Liver cirrhosis, hepatocellular carcinoma, diabetes mellitus, heart failure, arthritis, hypothyroidism, and chronic fatigue.

Portal Hypertension

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Other Liver Conditions

Symptoms:
abdominal swelling (ascites); enlarged spleen (splenomegaly); vomiting blood (hematemesis) due to variceal bleeding; dark, tarry stools (melena); confusion or altered mental state in severe cases (hepatic encephalopathy); fatigue

Root Cause:
Increased blood pressure within the portal venous system, often due to cirrhosis, fibrosis, or a blockage in the portal vein.

How it's Diagnosed: videos
Clinical evaluation, imaging studies (e.g., Doppler ultrasound, CT scan, MRI), endoscopy to assess varices, and measurement of hepatic venous pressure gradient (HVPG).

Treatment:
Addressing the underlying cause, managing complications like varices, ascites, and encephalopathy. Treatments include beta-blockers, endoscopic variceal banding, TIPS (transjugular intrahepatic portosystemic shunt), and in severe cases, liver transplantation.

Medications:
Nonselective beta-blockers (e.g., propranolol , nadolol ) to reduce portal pressure; vasoactive agents (e.g., octreotide ) to control variceal bleeding; diuretics (e.g., spironolactone , furosemide ) for ascites; antibiotics (e.g., norfloxacin ) to prevent infections in patients with varices.

Prevalence: How common the health condition is within a specific population.
Common among patients with advanced liver disease; prevalence depends on the underlying cause (e.g., cirrhosis affects approximately 2-3 per 1,000 adults annually).

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Chronic liver disease, cirrhosis, hepatitis B or C infection, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and thrombosis in the portal vein.

Prognosis: The expected outcome or course of the condition over time.
Varies depending on the underlying cause and effectiveness of treatment. With proper management, complications can be controlled, though severe cases may require liver transplantation.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Variceal bleeding, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, and increased mortality risk in advanced cases.

Hepatic Encephalopathy

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Neurological Manifestations of Liver Disease

Symptoms:
confusion; difficulty concentrating; personality changes; disorientation; sleep disturbances; tremors (asterixis); slurred speech; lethargy; in severe cases, coma

Root Cause:
Build-up of toxins like ammonia in the bloodstream due to the liver's inability to properly detoxify them, often secondary to liver dysfunction or portal-systemic shunting.

How it's Diagnosed: videos
Clinical assessment, blood tests (elevated ammonia levels), liver function tests, and imaging studies to rule out other causes of altered mental status.

Treatment:
Reducing ammonia production and absorption using dietary protein restriction, lactulose (to acidify the colon and reduce ammonia absorption), and antibiotics like rifaximin (to reduce ammonia-producing gut bacteria).

Medications:
Lactulose (a non-absorbable sugar that traps ammonia in the colon), rifaximin (a gut-specific antibiotic), and sometimes neomycin or metronidazole (alternative antibiotics for reducing ammonia production).

Prevalence: How common the health condition is within a specific population.
Common among individuals with advanced liver disease, with approximately 30-45% of cirrhotic patients developing some form of hepatic encephalopathy.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Advanced liver disease, cirrhosis, portal hypertension, gastrointestinal bleeding, infections, dehydration, electrolyte imbalances, and high-protein diets.

Prognosis: The expected outcome or course of the condition over time.
Reversible with treatment in early stages, but recurrent episodes are common unless the underlying liver dysfunction is addressed. Severe or untreated cases may lead to permanent brain damage or death.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Recurrent episodes, progressive cognitive impairment, reduced quality of life, coma, and increased mortality.

Budd-Chiari Syndrome

Specialty: Gastrointestinal

Category: Liver Disorders

Sub-category: Vascular Liver Disorders

Symptoms:
abdominal pain, especially in the upper right quadrant; ascites; enlarged liver (hepatomegaly); jaundice; nausea; vomiting; swelling in the legs; fatigue

Root Cause:
Obstruction of the hepatic veins, often caused by thrombosis or compression, leading to impaired blood flow out of the liver and subsequent congestion and damage.

How it's Diagnosed: videos
Doppler ultrasound, CT scan, MRI, liver biopsy (in some cases), and blood tests to identify hypercoagulable states.

Treatment:
Addressing the underlying cause (e.g., anticoagulation for thrombosis, thrombolysis), managing complications like ascites, and restoring venous outflow via angioplasty, TIPS, or surgical shunting. Liver transplantation may be needed in severe cases.

Medications:
Anticoagulants (e.g., warfarin , heparin ) to prevent further clot formation; diuretics (e.g., spironolactone , furosemide ) for managing ascites; thrombolytic agents (e.g., tissue plasminogen activator) in selected cases.

Prevalence: How common the health condition is within a specific population.
Rare, with an estimated incidence of 1 in 100,000; more common in patients with underlying hypercoagulable conditions.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Hypercoagulable states (e.g., protein C or S deficiency, antiphospholipid syndrome), polycythemia vera, myeloproliferative disorders, oral contraceptive use, pregnancy, and liver tumors.

Prognosis: The expected outcome or course of the condition over time.
Variable, depending on the extent of liver damage and the success of treatment. Early intervention can significantly improve outcomes, but severe or untreated cases may lead to liver failure.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Liver failure, portal hypertension, ascites, hepatic encephalopathy, and death in advanced or untreated cases.